Where can I find news about SLDX?

The latest headlines, third-party analysis, and SEC filings for Stella Diagnostics Inc. (SLDX) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are SLDX's SEC filings?

Stella Diagnostics Inc. (SLDX)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are SLDX's earnings call transcripts?

Full earnings call transcripts for Stella Diagnostics Inc. (SLDX) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

SLDX

Stella Diagnostics Inc.

OTC·Medical, Diagnostics & Research · Healthcare

$0.01$0.00+0.00%

Market cap$786.26K·Market closed·Aug 25 8:00 PM UTC

News & Analysis

Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference
STLA101 panel of 8 proprietary biomarkers can differentiate between the stages of esophageal cancer invasion and has previously demonstrated predictive power of detecting hallmarks of carcinogenesis in precancerous esophageal tissue STLA101 panel of 8 proprietary biomarkers can differentiate between the stages of esophageal cancer invasion and has previously demonstrated predictive power of detecting hallmarks of carcinogenesis in precancerous esophageal tissue
globenewswire.comMay 11, 2022 · 8:30 AM
Stella Diagnostics to Present at “Next Big Thing” Session at Society of American Gastroenterologists and Endoscopic Surgeons Annual Meeting
DENVER, March 02, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and cancerous esophageal diseases, today announced its abstract, “Multi-Institutional Study Assessing STLA101 Assay Performance for the Detection of Cancerous Progression in Barrett's Esophagus”, has been selected for the Next Big Thing session at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2022 Annual Meeting. The congress will be held March 16-19, 2022, at the Colorado Convention Center in Denver.
globenewswire.comMar 2, 2022 · 8:30 AM

SEC Filings

No recent filings indexed.

Frequently Asked Questions About SLDX

Where can I find news about SLDX?: The latest headlines, third-party analysis, and SEC filings for Stella Diagnostics Inc. (SLDX) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are SLDX's SEC filings?: Stella Diagnostics Inc. (SLDX)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are SLDX's earnings call transcripts?: Full earnings call transcripts for Stella Diagnostics Inc. (SLDX) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

Stella Diagnostics Inc.

Frequently Asked Questions About SLDX

Stella Diagnostics Inc.

Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference

Stella Diagnostics to Present at “Next Big Thing” Session at Society of American Gastroenterologists and Endoscopic Surgeons Annual Meeting

Frequently Asked Questions About SLDX

Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference

Stella Diagnostics to Present at “Next Big Thing” Session at Society of American Gastroenterologists and Endoscopic Surgeons Annual Meeting